Search Result

Results for "

SARS-CoV-2 viral replication

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (64) AMPK (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Casein Kinase (1) Cholinesterase (ChE) (1) COX (2) Cytochrome P450 (1) DNA Methyltransferase (2) DNA/RNA Synthesis (6) Drug Derivative (2) E1/E2/E3 Enzyme (1) Endogenous Metabolite (2) Flavivirus (2) Glycosyltransferase (1) HBV (3) HCV (4) IFNAR (1) Influenza Virus (3) Integrin (1) JNK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (2) Lipoxygenase (2) MMP (1) NF-κB (1) p38 MAPK (1) PERK (1) Phosphatase (1) PKC (1) PROTACs (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Reverse Transcriptase (2) STING (1) TGF-beta/Smad (1) Toll-like Receptor (TLR) (1) Tyrosinase (1) Virus Protease (11)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Infection (64) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (3)

By Targets:

SARS-CoV (64)

AMPK (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Casein Kinase (1)

Cholinesterase (ChE) (1)

COX (2)

Cytochrome P450 (1)

DNA Methyltransferase (2)

DNA/RNA Synthesis (6)

Drug Derivative (2)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (2)

Flavivirus (2)

Glycosyltransferase (1)

HBV (3)

HCV (4)

IFNAR (1)

Influenza Virus (3)

Integrin (1)

JNK (1)

Keap1-Nrf2 (1)

Lactate Dehydrogenase (2)

Lipoxygenase (2)

MMP (1)

NF-κB (1)

p38 MAPK (1)

PERK (1)

Phosphatase (1)

PKC (1)

PROTACs (1)

RAR/RXR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Reverse Transcriptase (2)

STING (1)

TGF-beta/Smad (1)

Toll-like Receptor (TLR) (1)

Tyrosinase (1)

Virus Protease (11)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Infection (64)

Inflammation/Immunology (5)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13324

Bardoxolone methyl Maximum Cited Publications 41 Publications Verification RTA 402; NSC 713200; CDDO Methyl ester	Keap1-Nrf2 SARS-CoV Virus Protease	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bardoxolone (CDDO; RTA 401) methyl is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC₅₀ value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD) .

HY-N1996

Chebulagic acid 5 Publications Verification	COX Lipoxygenase SARS-CoV Influenza Virus	Infection Inflammation/Immunology
Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against *SARS-CoV-2* viral replication with an EC₅₀ of 9.76 μM.

HY-172437

Secutrelvir S-892216	Virus Protease SARS-CoV	Infection
Secutrelvir is an oral SARS-CoV-2 3C-like protease (3CLpro) inhibitor and antiviral agent, with IC₅₀ values of 0.655 nM and 0.697 nM against SARS-CoV-2 3CLpro, respectively. Secutrelvir forms a reversible covalent bond with the catalytic cysteine C145 of SARS-CoV-2 3CLpro, thereby inhibiting viral replication. Secutrelvir exhibits activity against multiple SARS-CoV-2 variants and can be used in research related to coronavirus disease 2019 (COVID-19) .

HY-168034

diABZI-4	STING Integrin NF-κB SARS-CoV	Infection Inflammation/Immunology
diABZI-4 is a STING activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the TBK1-IRF3 and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, *SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral* disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms .

HY-172760

CIM-834	SARS-CoV	Infection
CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .

HY-131603

Lamivudine triphosphate 3TCTP	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-137958

Bemnifosbuvir hemisulfate 4 Publications Verification AT-527	HCV SARS-CoV	Infection
Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide proagent, is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₉₀=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity .

HY-N3266

Methyl rosmarinate	Tyrosinase Phosphatase Cholinesterase (ChE) SARS-CoV PERK JNK p38 MAPK TGF-beta/Smad Apoptosis Reactive Oxygen Species (ROS) AMPK MMP	Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
Methyl rosmarinate is an orally active hydroxycinnamic acid. Methyl rosmarinate exhibits an IC₅₀ of 24.70 μM and a K_i of 15.29 μM against PTP1B, an IC₅₀ of 41.46 μg/mL against BChE, a K_i of 0.61 mM against mushroom tyrosinase, and an IC₅₀ of 2.50 μM against *SARS-CoV-2* 3CLpro. Methyl rosmarinate downregulates the phosphorylation levels of ERK, JNK, p38, Smad2 and Smad3. Methyl rosmarinate activates erythrocyte BPGM and promotes the production of 2,3-BPG. Methyl rosmarinate induces apoptosis of fibroblasts. Methyl rosmarinate prolongs the survival time of hypoxic mice. Methyl rosmarinate improves insulin sensitivity. Methyl rosmarinate binds to SARS-CoV-2 3CLpro and inhibits viral replication. Methyl rosmarinate induces glioblastoma cell death. Methyl rosmarinate activates the TGR5/AMPK axis and reduces the levels of ROS and MDA. Methyl rosmarinate shows inhibitory activity against MMP-1. Methyl rosmarinate can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, COVID-19, glioblastoma and myocardial ischemia-reperfusion injury .

HY-137958A

Bemnifosbuvir 4 Publications Verification AT-511	HCV SARS-CoV	Infection
Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₉₀=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity .

HY-147020

Coronastat NK01-63	SARS-CoV	Infection
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .

HY-128788

ddhCTP	DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase	Infection
ddhCTP is an endogenously produced pyrimidine base analog with a K_d of 17.0 nM for LLDH and an IC₅₀ of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-137984

Cnicin	SARS-CoV Apoptosis	Cancer
Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against *SARS-CoV-2. Cnicin inhibits the viral* replication of *SARS CoV-2* with an IC₅₀ of 1.18 μg/mL. Cnicin can promote functional nerve regeneration .

HY-145592

Ruzotolimod RO7020531; RG7854	Toll-like Receptor (TLR) SARS-CoV HBV	Infection
Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or *SARS-CoV-2* .

HY-170524

TDI-015051	SARS-CoV DNA Methyltransferase Cytochrome P450	Infection
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including *SARS-CoV-2* and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC₅₀ values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the K_a value against *SARS-CoV-2* is 0.061 nM .

HY-139165

AT-9010	SARS-CoV	Infection
AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit *SARS-CoV-2* replication .

HY-139165A

AT-9010 tetrasodium 1 Publications Verification	SARS-CoV	Infection
AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 tetrasodium can inhibit *SARS-CoV-2* replication .

HY-105721

Aranotin	SARS-CoV	Infection
Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising **SARS-CoV-2 replication** strong inhibitor. Aranotin has the potential for COVID-19 research .

HY-109072

Riamilovir	DNA/RNA Synthesis SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of *SARS-CoV-2* .

HY-162154

SARS-CoV-2-IN-75	SARS-CoV	Infection
SARS-CoV-2-IN-75 (compound 13) is a *SARS-CoV-2* inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC₆₈ (half-log reduction in viral titer) of 3 μM .

HY-178160

SARS-CoV-2 PLpro-IN-2	SARS-CoV Virus Protease	Infection
SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC₅₀=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC₅₀=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19 .

HY-175461

AVI-4206	SARS-CoV	Infection
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of *SARS-CoV-2* infection. AVI-4206 can be used the study of *SARS-CoV-2* infection .

HY-131603B

Lamivudine triphosphate TEA 3TCTP TEA	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-N1996R

Chebulagic acid (Standard)	Reference Standards COX Lipoxygenase SARS-CoV Influenza Virus	Infection Inflammation/Immunology
Chebulagic acid (Standard) is the analytical standard of Chebulagic acid. This product is intended for research and analytical applications. Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC₅₀ of 9.76 μM.

HY-174350

CK2-IN-15	Casein Kinase SARS-CoV	Infection
CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC₅₀ value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .

HY-144260

3CPLro-IN-1	SARS-CoV	Infection
3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-144263

3CPLro-IN-2	SARS-CoV	Infection
3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ and K_i of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-E70610

SARS-CoV-2 main protease	Virus Protease SARS-CoV	Infection
SARS-CoV-2 main protease is a main protease (Mpro) of SARS-CoV-2, which plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19 .

HY-161777

SARS-CoV-2 Mpro-IN-23	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC₅₀ of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC₅₀ of 0.02-0.52 μM .

HY-W760546

SARS-CoV-2 3CLpro-IN-15	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .

HY-164868

SARS-CoV-2-IN-106	SARS-CoV	Infection
SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC₅₀ values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively .

HY-155014

SARS-CoV-2-IN-44	SARS-CoV	Infection
SARS-CoV-2-IN-44, a inhibitor of *SARS-CoV-2, inhibits viral* replication, with an EC₅₀ of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .

HY-156325

SARS-CoV-2-IN-62	SARS-CoV	Infection
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of *SARS-CoV-2* replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 2.97 μM and 3.82 μM, respectively .

HY-156337

SARS-CoV-2-IN-63	SARS-CoV	Infection
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of *SARS-CoV-2* replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 1.99 μM and 1.92 μM, respectively .

HY-175460

SARS-CoV-2-IN-117	SARS-CoV	Infection
SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145435

SARS-CoV-2-IN-12	SARS-CoV	Infection
SARS-CoV-2-IN-12 (Compound 27) is a potent *SARS-CoV-2*-related 3C-like protease inhibitor (K_i=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19 .

HY-139165B

AT-9010 triethylamine	SARS-CoV	Infection
AT-9010 triethylamine，a triphosphate active metabolite of AT-527，is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit *SARS-CoV-2* replication .

HY-155527

SARS-CoV-2 Mpro-IN-9	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent *SARS-CoV-2* M ^pro inhibitor (IC₅₀=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC₅₀=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC₅₀>50 μM) .

HY-N144101

SARS-CoV MPro-IN-2	SARS-CoV	Infection
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against *SARS-CoV-2* infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-170523

RU-0415529	SARS-CoV DNA Methyltransferase	Infection
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .

HY-N3445

Jaceidin triacetate	SARS-CoV	Infection
Jaceidin triacetate(compound 54) is a natural compound isolated formmarulabark.Jaceidin triacetatecan inhibitSARS-CoV-2 Mpro, with theIC₅₀of 11.9μM.Jaceidin triacetateinhibits the replication of Sars-Cov-2 Viral in Vero-E6 cells .

HY-141841

SARS-CoV-2-IN-7	SARS-CoV	Infection
SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC₅₀ value (844 nM) in SARS-CoV-2-infected Vero E6 cells.

HY-161789

PROTAC SARS-CoV-2 Mpro degrader-3	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC₅₀=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC₅₀ of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .

HY-163857

SARS-CoV-2-IN-91	SARS-CoV	Infection
SARS-CoV-2-IN-91 (Compound 194) is an inhibitor for *SARS-CoV 2* with an EC₅₀ of 28.92 μM. SARS-CoV-2-IN-91 inhibits the viral -1 programmed ribosome frame shift (-1PRF) element, and thereby inhibits the replication of SARS-CoV 2 .

HY-N15365

Antcin B	Virus Protease SARS-CoV	Infection
Antcin B is a SARS-CoV-2 3-chymotrypsin-like protease (3CL Pro) inhibitor. Antcin B binds to multiple key amino acid residues of 3CL Pro(such as Leu141, Asn142, Glu166, His163, etc.) through hydrogen bonds, salt bridges, and hydrophobic interactions, thereby inhibiting the activity of 3CL Pro, blocking the cleavage process of viral polyproteins, and suppressing the replication of the SARS-CoV-2 virus in host cells. Antcin B is promising for research of COVID-19 .

HY-182292

SARS-CoV-2 3CLpro-IN-37		Infection
SARS-CoV-2 3CLpro-IN-37 is a non-covalent SARS-CoV-2 3CLpro inhibitor with an IC₅₀ of 3.2 nM. SARS-CoV-2 3CLpro-IN-37 blocks the cleavage and replication of viral polyproteins. SARS-CoV-2 3CLpro-IN-37 is applicable to research related to COVID-19 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SARS-CoV-2 viral replication

Inhibitors & Agonists

NaturalProducts

Natural
Products